DMPK studies often present challenges of limited sample volumes and/or high sensitivity requirements. The ionKey/MS System from Waters is a microfluidic-based LC-MS system that helps address both of these issues, but is it sufficiently robust and reliable for use as a routine analytical technology?
In this webcast, our speakers will share their experiences with ionKey/MS System, a novel plug and play microfluidic platform. Historically, implementation of microfluidic LC-MS platforms has forced a compromise between analytical performance and usability. The ionKey/MS System has been purposfully designed to address both of these issues.
Scientists looking to adopt this technology for the gains in sensitivity and reduction in solvent usage and sample volume have been frustrated by poor chromatographic performance and general lack of robustness that the currently available commercial systems offer. We will share the work of three such scientists, two working in an innovative pharma lab evaluating new biologics and the third a CRO performing both qualitative and quantitative analysis for drug metabolism studies. They will discuss their experience with the ionKey/MS System and the benefits it has yielded in their labs thus far.
What will you learn?
- What is the ionKey/MS System?
- How do microfluidic technologies work?
- Which studies benefit from the use of microfluidics based MS systems in the DMPK lab?
- How these results may change the course of drug development
Who should attend?
Pharmaceutical scientists and lab managers focused on bioanalysis of small and large molecules with the need for sample volume reduction, reduction in solvent usage and/or improvements in sensitivity that are beyond the capability of their current high end LC-MS systems in their labs.
RMI Laboratories LLC
Dr. Tiller obtained his Ph.D. from the Imperial College of Science, Technology and Medicine, London. His thesis work was on the structural elucidation of cell surface polysaccharides by mass spectrometry. Subsequently he worked for VG Analytical and VG Biotech (now part of Waters) dealing with sector and quadrupole based instrumentation. He has also worked for Finnigan (part of Thermo) as the product manager for the LCQ and LCQDECA instruments. Dr. Tiller has more than 15 years experience working in the Pharmaceutical industry initially at Glaxo in England and recently at Merck in the US. His focus has been the application of mass spectrometry in solving analytical problems, most recently the application of HRMS in metabolite Identification. In 2009 he co-founded RMI Laboratories a contract analytical lab that provides state-of-the-art qualitative analytical services, mainly metabolite profiling and biopharmaceutical qualification.
Jonathan Kehler is an Investigator in the Bioanalytical Science and Toxicokinetics department at GlaxoSmithKline Pharmaceuticals in King of Prussia, PA. He has worked in bioanalysis, metabolite identification, method development and managing teams in both GLP and high throughput discovery environments for over 18 years in the pharmaceutical and clinical industries. Current research interests include development of novel methods to quantitate biopharmaceuticals utilizing LC/MS/MS technology and techniques. He is also actively involved with the investigation of new technology to increase laboratory efficiency.
Thomas Mencken is an Investigator in the Bioanalytical Science and Toxicokinetics department at GlaxoSmithKline Pharmaceuticals in King of Prussia, PA. He has been involved with bioanalysis, analytical chemistry and quality control for 25 years. Currently, Thomas is focused on the development of quantitative assays for immunocapture LC-MS/MS for various biomolecules, and exploiting novel platforms to automate and simplify sample preparation processes.